221 related articles for article (PubMed ID: 34363719)
21. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
[TBL] [Abstract][Full Text] [Related]
22. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes R; Doleschall N; Connors K; Geary B; Meyer S
Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
[TBL] [Abstract][Full Text] [Related]
23. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.
Ayoub E; Wilson MP; McGrath KE; Li AJ; Frisch BJ; Palis J; Calvi LM; Zhang Y; Perkins AS
Nat Commun; 2018 Oct; 9(1):4239. PubMed ID: 30315161
[TBL] [Abstract][Full Text] [Related]
24. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
25. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract][Full Text] [Related]
26. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
Suzuki M
Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
[TBL] [Abstract][Full Text] [Related]
28. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
[TBL] [Abstract][Full Text] [Related]
29. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Marchesini M; Gherli A; Simoncini E; Tor LMD; Montanaro A; Thongon N; Vento F; Liverani C; Cerretani E; D'Antuono A; Pagliaro L; Zamponi R; Spadazzi C; Follini E; Cambò B; Giaimo M; Falco A; Sammarelli G; Todaro G; Bonomini S; Adami V; Piazza S; Corbo C; Lorusso B; Mezzasoma F; Lagrasta CAM; Martelli MP; La Starza R; Cuneo A; Aversa F; Mecucci C; Quaini F; Colla S; Roti G
Nat Commun; 2024 Jun; 15(1):4739. PubMed ID: 38834613
[TBL] [Abstract][Full Text] [Related]
30. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
Benajiba L; Alexe G; Su A; Raffoux E; Soulier J; Hemann MT; Hermine O; Itzykson R; Stegmaier K; Puissant A
Leukemia; 2019 Mar; 33(3):800-804. PubMed ID: 30390009
[No Abstract] [Full Text] [Related]
31. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
32. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
34. Acute Myeloid Leukemia (AML): Upregulation of BAALC/MN1/MLLT11/EVI1 Gene Cluster Relate With Poor Overall Survival and a Possible Linkage With Coexpression of MYC/BCL2 Proteins.
Akhter A; Farooq F; Elyamany G; Mughal MK; Rashid-Kolvear F; Shabani-Rad MT; Street L; Mansoor A
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):483-488. PubMed ID: 28362701
[TBL] [Abstract][Full Text] [Related]
35. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
36. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
37. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
38. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
39. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Birdwell C; Fiskus W; Kadia TM; DiNardo CD; Mill CP; Bhalla KN
Blood Cancer J; 2021 Mar; 11(3):64. PubMed ID: 33753715
[TBL] [Abstract][Full Text] [Related]
40. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
